The role of glucagon-like peptide 1 (GLP-1) receptor agonists in the prevention and treatment of diabetic kidney disease: insights from the AMPLITUDE-O trial
References Toet, H., Piedrafita, D
Next, a metabolic-syndrome study reported higher energy expenditure, increased fatty-acid oxidation, reduced fat-mass accumulation, and improved insulin sensitivity in mouse models
In contrast to human tissue and cultured cells, it has been demonstrated that Nrf2 activity is consistently elevated in the spinal cord of SOD1 G93A rodent models of ALS, and the increase of Nrf2, thioredoxin, HSP-70, HO1, NQO1, GCLC, and GCLM protein levels follows disease progression in the lumbar spinal cord but not cortex [264, 265]
Br J Ophthalmol 101:12341237
Amiel SA, Aschner P, Childs B, Cryer PE, De Galan BE, Frier BM, et al